Enzalutamide

Category: pharmacological

Aliases: Xtandi

Pharmacological Mechanism

Androgen receptor antagonist — blocks AR ligand binding, AR nuclear translocation, and AR-DNA binding. Stronger than first-generation bicalutamide. Castration-resistant prostate cancer. Strong CYP3A4 inducer (auto-induces own clearance + lowers many co-medications).

Half-Life (t½)

PO: 130h

Dosing Guidelines

• PO: Typical 160 mg (Range: 40–160 mg)

Target Organ Systems

• endocrine
• digestive
• reproductive

Pathways It Modulates

• Aromatase + androgen receptor (inhibitor) — androgen receptor (AR antagonist, no agonist activity)

Chemical Identifiers

• PubChem CID: 15951529
• Formula: C21H16F4N4O2S
• Molecular weight: 464.44 g/mol
• InChIKey: WXCXUHSOUPDCQV-UHFFFAOYSA-N
• SMILES: CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C

References

• PMID 30642613
• PMID 19359544